ClinicalTrials.gg
RecruitingNCT07449702Updated Oct 23, 2026

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

A Phase 2 interventional study of ORKA-001 in Plaque Psoriasis, sponsored by Oruka Therapeutics, Inc.. Recruiting at 39 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Oruka Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 23, 20265 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Planned enrollment
175th of 673
240 · median 77
Started
2026
with 15 others
Phase 2
200 of 764
5 open now
Primary completion
2030-05
later than 74 of 85 live
Registered
752nd of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 175th largest by planned enrollment of the 673 interventional ones that give a count, is one of 16 that started in 2026, is one of 200 in phase 2, reaches primary completion later than 74 of the 85 other live ones, and was the 752nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

49 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Read the detailed description

This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Phase 2
  • ORKA-001
  • Open Label Extension
  • OLE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed by participants from previous trial choosing to transition into the OLE.
  2. Participants who have successfully completed the preceding trial.
  3. For women of , must have a negative urine pregnancy test at Baseline visit.
  4. For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective

Exclusion criteria

Exclusion Criteria:

  1. Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
  2. Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
  3. Evidence of current or previous disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
  4. Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
  5. Participant is pregnant or breastfeeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    ORKA-001 Once Yearly (High Dose)

    Participants will receive ORKA-001 once a year per OLE protocol.

    Drug: ORKA-001

  • Experimental
    ORKA-001 Once Yearly (Low Dose)

    Participants will receive ORKA-001 once a year per OLE protocol.

    Drug: ORKA-001

  • Experimental
    ORKA-001 Twice Yearly

    Participants will receive ORKA-001 every 6 months per OLE protocol.

    Drug: ORKA-001

  • No intervention
    No Drug

    Participants will receive no drug until protocol defined PASI response criterion is met.

Interventions

  • ORKA-001 administered by subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)

    Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms.

    Time frame: Day 1 through Week 144

Secondary outcomes

  1. Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Day 1 through Week 96

  2. Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Day 1 through Week 96

  3. Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Day 1 through Week 96

  4. Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Time Frame: Day 1 through Week 96

  5. Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline

    Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Day 1 through Week 96

  6. Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Day 1 through Week 96

  7. Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Day 1 through Week 96

  8. PASI Score Over Time

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Day 1 through Week 96

  9. IGA Score Over Time

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Day 1 through Week 96

07

Study locations

39 of 39 sites recruiting
  • Oruka Therapeutics Investigative Site
    Phoenix, Arizona 85032, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    North Little Rock, Arkansas 72117, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Fountain Valley, California 92708, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Los Angeles, California 90045, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Los Angeles, California 90095, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    San Diego, California 92123, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Santa Ana, California 92701, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Santa Monica, California 90403, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Cromwell, Connecticut 06416, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Miami, Florida 33126, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Rolling Meadows, Illinois 60008, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Plainfield, Indiana 46168, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Bowling Green, Kentucky 42104, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Rockville, Maryland 20850, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Boston, Massachusetts 02111, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Detroit, Michigan 48202, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    New York, New York 10023, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    New York, New York 10029, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Cleveland, Ohio 44106, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Mason, Ohio 45040, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Portland, Oregon 97201, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Portland, Oregon 97210, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Frisco, Texas 75033, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Houston, Texas 77004, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Webster, Texas 77598, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Norfolk, Virginia 23502, United States
    Recruiting
  • Oruka Therapeutics Investigative Site
    Edmonton, Alberta T5J 3S9, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Edmonton, Alberta T6G 1C3, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Surrey, British Columbia V3R 6A7, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Surrey, British Columbia V3V 0C6, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Fredericton, New Brunswick E3B IG9, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Ajax, Ontario L1S7K8, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    London, Ontario N6H 5L5, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Markham, Ontario L3P 1X3, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Peterborough, Ontario K9J 5K2, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Toronto, Ontario M4W 2N4, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Waterloo, Ontario N2J 1C4, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Montreal, Quebec H2X2V1, Canada
    Recruiting
  • Oruka Therapeutics Investigative Site
    Québec, Quebec G1V4X7, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for May 2030, 51 months after the start.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 51 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 4, 2026
StartActual
Feb 23, 2026
Primary completionEst.
May 2030
CompletionEst.
Jul 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added
Show 5 added (4 United States, 1 Canada)
  • Oruka Therapeutics Investigative Site · North Little Rock, United States
  • Oruka Therapeutics Investigative Site · Los Angeles, United States
  • Oruka Therapeutics Investigative Site · Plainfield, United States
  • Oruka Therapeutics Investigative Site · Cleveland, United States
  • Oruka Therapeutics Investigative Site · Fredericton, Canada
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    5 sites added
    Show 5 added (4 United States, 1 Canada)
    • Oruka Therapeutics Investigative Site · North Little Rock, United States
    • Oruka Therapeutics Investigative Site · Los Angeles, United States
    • Oruka Therapeutics Investigative Site · Plainfield, United States
    • Oruka Therapeutics Investigative Site · Cleveland, United States
    • Oruka Therapeutics Investigative Site · Fredericton, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07449702
Lead sponsor
Oruka Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Feb 23, 2026
Primary completion
May 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

Oruka Clinical Trials Information
Contact
clinicaltrials@orukatx.com
781-560-0299

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avrukibart

Start the discussion